Correspondence
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versushost disease Chronic GVHD (cGVHD) occurs in about 25% of pediatric patients receiving allogeneic bone marrow transplantation. 1 It may be limited or extensive with multiorgan involvement. Acute GVHD (aGVHD) develops in about 30-60% of HLA-identical transplants from siblings and mainly involves skin, liver and gut. 2 Since 1991, published data report that drug-resistant cGVHD involving skin and oral mucosa can benefit from psoralen and ultraviolet A irradiation (PUVA therapy), which consists of exposure to UVA after photosensitization with orally administered 8-MOP. [3] [4] [5] [6] This approach has also recently been considered to be effective in a few cases of aGVHD. 7 We describe four pediatric transplant patients successfully treated with PUVA therapy after failure of standard immunosuppressive therapies: we used an innovative procedure where 8-MOP is diluted in a bath and not administered orally. This kind of approach could reduce the possibility of systemic side-effects related to oral 8-MOP administration, and improves patient compliance. Furthermore, this procedure is currently adopted successfully for patients affected by dermatological diseases, such as psoriasis, where the autoimmune process could be involved as the major pathogenetic determinant. 8 Case 1 (see Table 1 ): Progressive refractory extensive cGVHD developed 8 months after BMT, involving the skin (lichen planus-like papulae and scleroderma), oral mucosa and muscoloskeletal system (contractures). For 26 months various combinations of steroids, CsA, azathioprine (AZA), mycophenolate (MMF) were used, but the cGVHD did not resolve. Consequently, bath PUVA treatment was started in October 1999 and immunosuppressive therapy was tapered to just one drug. After 62 exposures administered over 6 months, the patient's skin and oral lesions improved significantly.
Case 2 (see Table 1 ): Progressive extensive cGVHD developed 3 months after transplant, involving the skin, oral mucosa and gut. Standard immunosuppression treatments (MMF, AZA, CsA) failed to control cGVHD and extracorporeal photochemotherapy was interrupted after 20 procedures due to poor venous access. The skin lesions presented as generalized follicular lichen planus-like eruptions and scleroderma; in addition, large erosions were present on the tongue, oral mucosa and lips: mucosal biopsy confirmed GVHD. Muscoloskeletal contractures occurred at different sites. In September 1999, bath PUVA therapy was started, and immunosuppression was tapered except for CsA. Improvement in the skin lesions was evident after 12 procedures. Bath PUVA therapy was continued without side-effects for a total of 70 procedures over 12 months: the skin had almost completely cleared and even the oral lesions showed a marked improvement, despite persistence of mild leukoplakia of the tongue (see Figures 1 and 2 ). Case 3 (see Table 1 ): Extensive cutaneous cGVHD developed 3 months after BMT. The skin lesions presented as generalized follicular lichen-planus-like eruptions. CsA was discontinued due to progressive lesions and acute renal failure. Bath PUVA therapy was started in September 1999, and continued for a total of 13 procedures with significant clinical improvement. Unfortunately the child developed fungal pneumonia and died 1 month later.
Case 4 (see Table 1 ): aGVHD grade I (skin grade II, gut grade I) developed 16 days after BMT. CsA was discontinued due to acute renal failure and bath PUVA therapy was started from day +48 with a complete resolution of GVHD after 22 treatments, despite the persistence of slight hyperpigmentation. By day +210 post BMT the patient had no signs of GVHD and is now receiving MMF at a dose of 500 mg/day, as the only GVHD treatment.
The bath PUVA therapy protocol consists of 50 ml of 8-MOP (0.5% in ethanol solution at 95%) diluted in 83 l of water at 37°C. Patients dip for 20 min before exposure to UVA (ocular spectrum 315-380 nm), according to the protocol adopted by our Dermatology Department which is derived from the British Photodermatology Group schedule. 8 UVA irradiation is performed after an evaluation of the minimal phototoxicity dose for each patient. The initial dose varies between 0.3 and 0.5 J/m 2 , with subsequent increments of 0.3 and 0.5 J/m 2 according to clinical response. Treatments are given three times per week until clearing or improvement; maintenance treatment consists of procedures administered twice weekly and, finally, once a week for 6 to 12 months.
To date, few data have proven the efficacy of PUVA therapy in aGVHD. 7 The complete remission obtained in case No. 4 is encouraging, but is isolated evidence that this therapy could represent an innovative second-line strategy for the treatment of aGVHD, especially for patients with drug-related complications due to standard immunosuppressive therapy.
In the other three cases with cGVHD which did not benefit from prolonged conventional therapy, the introduction of bath PUVA therapy led to clinical improvement with a reduction of immunosuppressive drugs. Furthermore, this therapy was well tolerated with no evidence of gastrointestinal or hepatic side-effects while nausea and vomiting are reported to occur in 30% and 10% respectively, after 8-MOP systemic administration. 9 No episodes of skin phototoxicity after bath PUVA were observed in our patients, with the exception of a mild and transient erythema due to UVA exposure. Other treatments have recently been advocated as useful for resistant cGVHD (MMF 10 or extracorporeal photochemotherapy, 11 ) but sometimes adverse effects have been responsible for their discontinuation. Although our experience is encouraging, we are aware that only a consistent clinical trial could really validate the benefit of 8-MOP topical administration in the treatment of acute and chronic skin GVHD. 
